首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   100637篇
  免费   6108篇
  国内免费   435篇
耳鼻咽喉   1113篇
儿科学   2514篇
妇产科学   1783篇
基础医学   12466篇
口腔科学   1753篇
临床医学   10652篇
内科学   20242篇
皮肤病学   1339篇
神经病学   10082篇
特种医学   3898篇
外国民族医学   3篇
外科学   16340篇
综合类   1082篇
一般理论   131篇
预防医学   8226篇
眼科学   2080篇
药学   6487篇
中国医学   105篇
肿瘤学   6884篇
  2023年   563篇
  2022年   935篇
  2021年   2093篇
  2020年   1325篇
  2019年   2098篇
  2018年   2549篇
  2017年   1824篇
  2016年   1986篇
  2015年   2274篇
  2014年   3443篇
  2013年   4725篇
  2012年   7562篇
  2011年   7974篇
  2010年   4583篇
  2009年   4130篇
  2008年   7125篇
  2007年   7447篇
  2006年   7177篇
  2005年   6890篇
  2004年   6716篇
  2003年   6049篇
  2002年   5705篇
  2001年   839篇
  2000年   556篇
  1999年   889篇
  1998年   1219篇
  1997年   924篇
  1996年   748篇
  1995年   682篇
  1994年   589篇
  1993年   578篇
  1992年   440篇
  1991年   399篇
  1990年   322篇
  1989年   291篇
  1988年   277篇
  1987年   276篇
  1986年   241篇
  1985年   277篇
  1984年   305篇
  1983年   252篇
  1982年   333篇
  1981年   281篇
  1980年   221篇
  1979年   93篇
  1978年   127篇
  1977年   106篇
  1976年   78篇
  1975年   66篇
  1973年   69篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Animal and human studies suggest fish oil and green tea may have protective effect on prostate cancer. Fatty acid synthase (FAS) has been hypothesized to be linked to chemoprotective effects of both compounds. This study evaluated the independent and joint effects of fish oil (FO) and green tea supplement (epigallocatechin-3-gallate, EGCG) on FAS and Ki-67 levels in prostate tissue. Through a double-blinded, randomized controlled trial with 2 × 2 factorial design, 89 men scheduled for repeat prostate biopsy following an initial negative prostate biopsy were randomized into either FO alone (1.9 g DHA + EPA/day), EGCG alone (600 mg/day), a combination of FO and EGCG, or placebo. We used linear mixed-effects models to test the differences of prostate tissue FAS and Ki-67 by immunohistochemistry between pre- and post-intervention within each group, as well as between treatment groups. Results did not show significant difference among treatment groups in pre-to-post-intervention changes of FAS (P = 0.69) or Ki-67 (P = 0.26). Comparing placebo group with any of the treatment groups, we did not find significant difference in FAS or Ki-67 changes (all P > 0.05). Results indicate FO or EGCG supplementation for a short duration may not be sufficient to produce biologically meaningful changes in FAS or Ki-67 levels in prostate tissue.  相似文献   
3.
4.
The Yakima Valley Farm Workers Clinic (YVFWC) is one of the largest community health centers in the country with clinics throughout south-central Washington and northern Oregon. Its dental program consists of 14 dental clinics providing general and specialty services to the low-income populations it serves. Modeling itself after the YVFWC medical managed care program; the Dental program recently added value-based metrics to its dental practice after Oregon offered a value-based dental reimbursement plan in 2019. This is the first-step YVFWC's dental program that has taken to prepare for value-based reimbursement and transform its dental practice in order to reduce the disease burden in its patient population. The purpose of this article is to describe the processes YVFWC undertook to prepare itself for the new reimbursement model, which included the development of metrics, a metric validation process, a clinical dashboard, and a method for improving metrics. It also outlines its medical/dental integration improvement brought about by embedding hygienists into the medical primary care teams.  相似文献   
5.
6.
7.
8.
9.
10.
Multimodality primary therapies for breast cancer combined with earlier detection have led to a sharp decline in the death rate from breast cancer in the UK over the last 40 years in the face of a rising incidence. The latest UK statistics from Cancer Research UK report 55,122 new cases of breast cancer in 2015 with 11,563 deaths from breast cancer recorded in 2016. Crudely, this equates to a cure rate of around 80% for all comers and demonstrates a clear improvement in outcome with 50,285 new cases in 2011 and 11,716 deaths in 2012. Despite this good news, there are still significant numbers of women (and men) who suffer from either a local recurrence or metastatic disease following apparently successful treatment for early breast cancer (Stage I to III). Only a minority of individuals, 6.6% with the stage recorded at diagnosis, present with stage IV disease. This review considers the treatment options available to individuals with locally recurrent and advanced breast cancer (ABC).  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号